國立虎尾科技大學 |

Ovarian cancers = advances through international research cooperation (GINECO, ENGOT, GCIG) /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Ovarian cancers/ edited by Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lecuru.
Reminder of title:	advances through international research cooperation (GINECO, ENGOT, GCIG) /
other author:	Pujade-Lauraine, Eric.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	x, 286 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Ovaries - Cancer -
Online resource:	http://dx.doi.org/10.1007/978-3-319-32110-3
ISBN:	9783319321103

Ovarian cancers = advances through international research cooperation (GINECO, ENGOT, GCIG) /
Ovarian cancersadvances through international research cooperation (GINECO, ENGOT, GCIG) /[electronic resource] :edited by Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lecuru. - Cham :Springer International Publishing :2017. - x, 286 p. :ill., digital ;24 cm.

Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma.

This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level.

ISBN: 9783319321103

Standard No.: 10.1007/978-3-319-32110-3doiSubjects--Topical Terms:

1248237
Ovaries
--Cancer

LC Class. No.: RC280.O8

Dewey Class. No.: 616.99465

Ovarian cancers = advances through international research cooperation (GINECO, ENGOT, GCIG) /
LDR:04039nam a2200313 a 4500 001 956906
003 DE-He213
005 20161017170609.0
006 m d
007 cr nn 008maaau
008 201118s2017 gw s 0 eng d
020 $a 9783319321103 $q (electronic bk.)
020 $a 9783319321080 $q (paper)
024 7 $a 10.1007/978-3-319-32110-3 $2 doi
035 $a 978-3-319-32110-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.O8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99465 $2 23
090 $a RC280.O8 $b O96 2017
245 0 0 $a Ovarian cancers $h [electronic resource] : $b advances through international research cooperation (GINECO, ENGOT, GCIG) / $c edited by Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lecuru.
260 $a Cham : $c 2017. $b Springer International Publishing : $b Imprint: Springer,
300 $a x, 286 p. : $b ill., digital ; $c 24 cm.
505 0 $a Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma.
520 $a This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level.
650 0 $a Ovaries $x Cancer $x Research. $3 1248237
650 0 $a Ovaries $x Cancer $x Treatment. $3 680808
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Oncology. $3 593951
650 2 4 $a Gynecology. $3 644094
650 2 4 $a Surgical Oncology. $3 673742
650 2 4 $a Reproductive Medicine. $3 669081
650 2 4 $a Pathology. $3 668553
700 1 $a Pujade-Lauraine, Eric. $3 1248234
700 1 $a Ray-Coquard, Isabelle. $3 1248235
700 1 $a Lecuru, Fabrice. $3 1248236
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-32110-3
950 $a Medicine (Springer-11650)